Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
JFL Life SciencesNSE:JFLLIFE 73 EV-to-EBIT is 6.69 as of Aug. 28, 2026, which is 32% below its 10-year median of 9.88. GuruFocus rates NSE:JFLLIFE with a GF Score™ of 73/100 and a GF Value™ of ₹36.72 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 691 Drug Manufacturers companies, JFL Life Sciences ranks better than 83.21% on this metric.
JFL Life Sciences (NSE:JFLLIFE) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
JFL Life Sciences's Enterprise Value for the quarter that ended in Mar. 2025 was ₹681.3 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. JFL Life Sciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was ₹71.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JFL Life Sciences EV-to-EBIT Related Terms
JFL Life Sciences EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for JFL Life Sciences's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, JFL Life Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JFL Life Sciences EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, JFL Life Sciences's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where JFL Life Sciences's EV-to-EBIT falls into.
JFL Life Sciences's current Enterprise Value is ₹477.2 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. JFL Life Sciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was ₹71.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JFL Life Sciences (NSE:JFLLIFE) has a EV-to-EBIT of 6.69 as of Aug. 28, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on JFL Life Sciences and its competitors. This is 32% below median its historical median of 9.88. Over the past decade, JFL Life Sciences' EV-to-EBIT has ranged from 5.63 to 27.00. According to the industry distribution chart, JFL Life Sciences ranks #116 out of 691 companies in the Drug Manufacturers industry, placing it in the top 16.8%.
Is JFL Life Sciences' EV-to-EBIT too high?
JFL Life Sciences' current EV-to-EBIT of 6.69 is 32% below median its 10-year median of 9.88. Over the past 10 years, this metric has ranged from a low of 5.63 to a high of 27.00. The Drug Manufacturers industry median EV-to-EBIT is 15.71. JFL Life Sciences' value of 6.69 is 57.4% below this industry median. Based on the distribution chart, JFL Life Sciences ranks #116 out of 691 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, JFL Life Sciences has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does JFL Life Sciences' EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, JFL Life Sciences ranks #116 out of 691 companies for EV-to-EBIT. This places JFL Life Sciences in the top 17% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.71. JFL Life Sciences' value of 6.69 is 57.4% below this benchmark. Historically, JFL Life Sciences' own EV-to-EBIT has ranged from 5.63 to 27.00 over the past decade. While the company's 10-year median is 9.88 vs. the industry median of 15.71, JFL Life Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.71, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. JFL Life Sciences's current EV-to-EBIT of 6.69 is 57.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on JFL Life Sciences and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JFL Life Sciences's current EV-to-EBIT is 6.69, which is 32% below median its own 10-year median of 9.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JFL Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, JFL Life Sciences (NSE:JFLLIFE) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹36.72, compared to a current price of ₹10.75 — trading 70.7% below its estimated fair value. The current EV-to-EBIT is 6.69, which is 32% below median its 10-year median of 9.88 and 57.4% below the Drug Manufacturers industry median of 15.71. JFL Life Sciences' overall GF Score™ is 73/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For JFL Life Sciences (NSE:JFLLIFE), the current EV-to-EBIT is 6.69 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JFL Life Sciences (NSE:JFLLIFE) Overvalued in 2026?
Based on GuruFocus' analysis, JFL Life Sciences stock appears to be undervalued.
The current stock price of ₹10.75 is trading 70.7% below its estimated GF Value™ of ₹36.72.
GuruFocus considers JFL Life Sciences to be Significantly Undervalued.
Key valuation signals for NSE:JFLLIFE:
EV-to-EBIT: 6.69 (32% below median its 10-year median of 9.88)
GF Value™: ₹36.72 vs. price of ₹10.75 (70.7% below fair value)
Industry Position: 57.4% below the Drug Manufacturers median (#116 of 691)
No single metric tells the full story. See the NSE:JFLLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JFL Life Sciences Ltd is engaged in the business of manufacturing pharmaceutical products. The company's product portfolio consists of Dry powder injections (B-Lactam), Tablets and Capsules (B-Lactam) solid oral dosage forms, and general tablets and capsules. Its operating segment comprises of manufacturing and selling of pharmaceutical products. Geographically, the company sells its products both in India and outside India.
73GF Score
Get the complete analysis for NSE:JFLLIFE
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:JFLLIFE has been successfully added to your 
